Fundz
New|Fundz now works inside Claude2 min

Signals were just the beginning. Fundz is what’s next.

Only Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Insilico Medicine secures $123 million in Series E financing led by Value Partners. The funding focuses on advancing AI technologies in life sciences.

PRIVATEAug 20, 2026

Amount Raised

¥123 Million

Round Type

Series E

CambridgeBiotechnology

Investors

Pudong Venture CapitalPudong Development GroupValue Partners

Description

Insilico Medicine has closed a $123 million Series E financing round with Value Partners as the lead investor. This funding aims to integrate AI technologies within the life sciences sector. Value Partners, along with Pudong Venture Capital and Pudong Development Group, has laid the groundwork for this investment. The collaboration seeks to unlock significant opportunities in scientific discovery through AI advancements.

Company Information

Company

Insilico Medicine

Location

1000 Massachusetts Avenue, Suite 126

Cambridge, Massachusetts, United States

About

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

Fundz sees it the moment Insilico Medicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsFeng R., co-CEO, CSO, Head of Drug R&D hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Insilico Medicine's next move

See what Strategic adds

Insilico Medicine raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.